Last news
AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- ChemLex, a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside the close of a USD 45 million funding round...

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT...

The 4th China International Supply Chain Expo Set for Beijing in June 2026

The 4th China International Supply Chain Expo Set for Beijing in June 2026

Sustained Worldwide Outreach Drives Greater Collaboration Opportunities BEIJING, Dec. 7, 2025 /PRNewswire/ -- The 4th China International Supply Chain Expo ("CISCE," "the Expo") will be held in Beijing from June 22 to 26, 2026. To date, more than...

CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue

CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue

SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully...

All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs

All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs

HONG KONG, Dec. 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for...

Skymizerʼs HyperThought™ Wins "Best IP/Processor of the Yearˮ and "Most Promising Productˮ at EE Awards Asia 2025

Skymizerʼs HyperThought™ Wins "Best IP/Processor of the Yearˮ and "Most Promising Productˮ at EE Awards Asia 2025

TAIPEI, Dec. 7, 2025 /PRNewswire/ -- Skymizer today announced that its next-generation HyperThought™ LLM Accelerator IP has been awarded "Best IP/Processor of the Yearˮ and named the "Most Promising Productˮ at the prestigious EE Awards Asia 2025,...

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...

DWMaterials Accelerates Expansion into Secondary Battery and Advanced Materials Industries: "Aiming to Become a Global Market Leader"

DWMaterials Accelerates Expansion into Secondary Battery and Advanced Materials Industries: "Aiming to Become a Global Market Leader"

SEOUL, South Korea, Dec. 7, 2025 /PRNewswire/ -- DWMaterials is accelerating its expansion into the secondary battery and advanced materials industries, leveraging its next-generation electromagnetic separator technology as a foundation for growth....

1 ... 97 98 99 100 101 102 103 104 105 ... 3379
menu
menu